This article was originally published in The Gray Sheet
Executive SummaryCardiac electrophysiology products company's $3.25 mil. equity financing agreement is led by Cardiac Capital, which is 50% owned by EP MedSystems Chairman and CEO David Jenkins. Cardiac Capital will receive 1.5 mil. shares of common stock and warrants for 750,000 additional shares exercisable at $4, out of a total 1.63 mil. shares and 812,500 warrants. Jenkins has agreed not to sell any previously owned shares for one year after the deal closes. Proceeds will be used to expand the Mt. Arlington, New Jersey firm's sales, marketing and manufacturing capabilities. FDA has granted EP MedSystems' ALERT catheter expedited PMA review for treatment of atrial fibrillation
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.